Gem Pharmaceuticals Report issue

For profit Phase 2
Founded: Birmingham AL United States (2003)
Status: Acquired by Monopar Therapeutics (2017)

Organization Overview

First Clinical Trial
2003
NCT00003403
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

13-deoxydoxorubicin (2 trials)

Camsirubicin (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 1)

Sarcoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2